Estimating survival benefit in castrate metastatic prostate cancer: decision making in proceeding to a definitive phase III trial

Author： Verbel D.A.   Kelly W.K.   Smaletz O.   Regan K.   Curley T.   Heller G.   Scher H.I.  

Publisher： Elsevier

ISSN： 0090-4295

Source： Urology, Vol.61, Iss.1, 2003-01, pp. : 142-144

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phase II study of docetaxel and estramustine in metastatic androgen-independent prostate cancer

By Guimaraes T.   Bento M.J.   Pinho T.   Guedes d.C.R.   Pinto F.  

European Urology Supplements, Vol. 1, Iss. 1, 2002-01 ,pp. : 159-159

Elsevier

Access to resources Recommend Favorite

Assessment of the Feasibility and Impact of Shared Decision Making in Prostate Cancer

By Onel E.   Hamond C.   Wasson J.H.   Berlin B.B.   Ely M.G.   Laudone V.P.   Tarantino A.E.   Albertsen P.C.  

Urology, Vol. 51, Iss. 1, 1998-01 ,pp. : 63-66

Elsevier

Access to resources Recommend Favorite

Prostate Cancer Metastatic to the Omentum

By Kehinde E. O.   Abdeen S. M.   Al-Hunayan A.   Ali Y.  

Scandinavian Journal of Urology and Nephrology, Vol. 36, Iss. 3, 2002-06 ,pp. : 225-227

Informa Healthcare

Access to resources Recommend Favorite

Prostate cancer metastatic to skin

By Leonard G.D.   Zhuang S.H.   Dahut W.  

Urology, Vol. 61, Iss. 2, 2003-02 ,pp. : 456-457

Elsevier

Access to resources Recommend Favorite

Prostate Specific Antigen: A Prognostic Marker of Survival in Good Prognosis Metastatic Prostate Cancer? (EORTC 30892)

By Collette L.   de Reijke T.M.   Schroder F.H.   Members of the EORTC Genito-Urinary Group  

European Urology, Vol. 44, Iss. 2, 2003-08 ,pp. : 182-189

Elsevier

Access to resources Recommend Favorite